Patents by Inventor Kei Kurita

Kei Kurita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Marker peptide for determining risk of developing metabolic syndrome, and use thereof
    Patent number: 10168339
    Abstract: It is an object of the present invention to provide a marker substance capable of accurately determining a risk of developing metabolic syndrome in vivo. That is, the present invention provides the followings: a marker peptide for determining the risk of developing the metabolic syndrome; an antibody or an aptamer bound to the marker peptide for determining the risk of developing the metabolic syndrome; a microarray in which the antibody or the aptamer bound to the marker peptide for determining the risk of developing the metabolic syndrome has been immobilized on a carrier; a method for determining the risk of developing the metabolic syndrome, comprising measuring an amount or the presence or absence of the marker peptide for determining the risk of developing the metabolic syndrome in a biological sample collected from a subject; and a kit for determining the risk of developing the metabolic syndrome, comprising the antibody or the aptamer or comprising the microarray.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: January 1, 2019
    Assignee: LION CORPORATION
    Inventors: Chiyoko Uchiyama, Kei Kurita, Eriko Fukushima, Riichi Maki
  • Marker peptide for determining risk of hyperglycemia and use thereof
    Patent number: 9970946
    Abstract: The object of the present invention is to provide a marker substance capable of determining a risk of hyperglycemia in vivo with high accuracy. The present invention provides the following: a marker peptide for determining the risk of hyperglycemia; an antibody or an aptamer bound to the marker peptide for determining the risk of hyperglycemia; a microarray wherein the antibody or the aptamer to be bound to the marker peptide for determining the risk of hyperglycemia has been immobilized onto a carrier; a method of determining the risk of hyperglycemia wherein an amount or the presence/absence of the marker peptide for determining the risk of hyperglycemia is measured in a biological sample collected from a subject; and a kit for determining the risk of hyperglycemia comprising the antibody or the aptamer, or the microarray.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: May 15, 2018
    Assignee: LION CORPORATION
    Inventors: Chiyoko Uchiyama, Kei Kurita
  • Internal composition
    Patent number: 9480672
    Abstract: An object of the present invention is to provide an internal composition capable of exerting various physiological functions such as a brain-function improving function. That is, the present invention provides an internal composition including docosahexaenoic acid and capsanthin, or docosahexaenoic acid, capsanthin, lutein, and zeaxanthin as active ingredients.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: November 1, 2016
    Assignee: LION CORPORATION
    Inventors: Hiroki Takenaka, Yasuharu Ishihara, Naoki Ichiyanagi, Misato Koakutsu, Kei Kurita
  • Internal composition
    Patent number: 9457001
    Abstract: An object of the present invention is to provide an internal composition capable of exerting various physiological functions such as a brain-function improving function. That is, the present invention provides an internal composition including docosahexaenoic acid and capsanthin, or docosahexaenoic acid, capsanthin, lutein, and zeaxanthin as active ingredients.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: October 4, 2016
    Assignee: LION CORPORATION
    Inventors: Hiroki Takenaka, Yasuharu Ishihara, Naoki Ichiyanagi, Misato Koakutsu, Kei Kurita
  • INTERNAL COMPOSITION
    Publication number: 20160067203
    Abstract: An object of the present invention is to provide an internal composition capable of exerting various physiological functions such as a brain-function improving function. That is, the present invention provides an internal composition including docosahexaenoic acid and capsanthin, or docosahexaenoic acid, capsanthin, lutein, and zeaxanthin as active ingredients.
    Type: Application
    Filed: July 10, 2014
    Publication date: March 10, 2016
    Applicant: LION CORPORATION
    Inventors: Hiroki TAKENAKA, Yasuharu ISHIHARA, Naoki ICHIYANAGI, Misato KOAKUTSU, Kei KURITA
  • MARKER PEPTIDE FOR DETERMINING RISK OF HYPERGLYCEMIA AND USE THEREOF
    Publication number: 20150285821
    Abstract: The object of the present invention is to provide a marker substance capable of determining a risk of hyperglycemia in vivo with high accuracy. The present invention provides the following: a marker peptide for determining the risk of hyperglycemia; an antibody or an aptamer bound to the marker peptide for determining the risk of hyperglycemia; a microarray wherein the antibody or the aptamer to be bound to the marker peptide for determining the risk of hyperglycemia has been immobilized onto a carrier; a method of determining the risk of hyperglycemia wherein an amount or the presence/absence of the marker peptide for determining the risk of hyperglycemia is measured in a biological sample collected from a subject; and a kit for determining the risk of hyperglycemia comprising the antibody or the aptamer, or the microarray.
    Type: Application
    Filed: December 10, 2013
    Publication date: October 8, 2015
    Applicant: LION CORPORATION
    Inventors: Chiyoko Uchiyama, Kei Kurita
  • MARKER PEPTIDE FOR DETERMINING RISK OF DEVELOPING METABOLIC SYNDROME, AND USE THEREOF
    Publication number: 20150160239
    Abstract: It is an object of the present invention to provide a marker substance capable of accurately determining a risk of developing metabolic syndrome in vivo. That is, the present invention provides the followings: a marker peptide for determining the risk of developing the metabolic syndrome; an antibody or an aptamer bound to the marker peptide for determining the risk of developing the metabolic syndrome; a microarray in which the antibody or the aptamer bound to the marker peptide for determining the risk of developing the metabolic syndrome has been immobilized on a carrier; a method for determining the risk of developing the metabolic syndrome, comprising measuring an amount or the presence or absence of the marker peptide for determining the risk of developing the metabolic syndrome in a biological sample collected from a subject; and a kit for determining the risk of developing the metabolic syndrome, comprising the antibody or the aptamer or comprising the microarray.
    Type: Application
    Filed: December 27, 2012
    Publication date: June 11, 2015
    Applicant: LION CORPORATION
    Inventors: Chiyoko Uchiyama, Kei Kurita, Eriko Fukushima, Riichi Maki